Biselective remodeling of the melanoma tumor microenvironment prevents metastasis and enhances immune activation in mouse models
(1) Afratis NA (2) Parikh S (3) Adir I (4) Parikh R (5) Solomonov I (6) Kollet O (7) Gelb S (8) Sade Y (9) Vaknine H (10) Zemser-Werner V (11) Brener R (12) Nizri E (13) Hershkovitz D (14) Ricard-Blum S (15) Levy C (16) Sagi I
Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models
(1) Ghasemi A (2) Martinez-Usatorre A (3) Liu Y (4) Demagny H (5) Li L (6) Mohammadzadeh Y (7) Hurtado A (8) Hicham M (9) Henneman L (10) Pritchard CEJ (11) Speiser DE (12) Migliorini D (13) De Palma M
(1) Ghasemi A (2) Martinez-Usatorre A (3) Liu Y (4) Demagny H (5) Li L (6) Mohammadzadeh Y (7) Hurtado A (8) Hicham M (9) Henneman L (10) Pritchard CEJ (11) Speiser DE (12) Migliorini D (13) De Palma M
Author Info: (1) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer
Author Info: (1) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (2) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (3) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (4) Laboratory of Metabolic Signaling, Institute of Bioengineering, EPFL, Lausanne, Switzerland. (5) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (6) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (7) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (8) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. (9) Animal Modeling Facility, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands. (10) Animal Modeling Facility, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands. (11) Department of Oncology, University of Lausanne (UNIL), Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. (12) Agora Cancer Research Center, Lausanne, Switzerland. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. Department of Oncology, Geneva University Hospital (HUG), Geneva, Switzerland. Center for Translational Research in Onco-Hematology, University of Geneva (UNIGE), Geneva, Switzerland. (13) Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. michele.depalma@epfl.ch. Agora Cancer Research Center, Lausanne, Switzerland. michele.depalma@epfl.ch. Swiss Cancer Center Lman (SCCL), Lausanne, Switzerland. michele.depalma@epfl.ch.
Citation: Nat Commun 2025 Oct 15 16:9148 Epub10/15/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41093860
Tags:
A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice
(1) Cao W (2) Chen J (3) Fu Y (4) Jiang H (5) Gao Y (6) Huang H (7) Fu YX (8) Wang W
(1) Cao W (2) Chen J (3) Fu Y (4) Jiang H (5) Gao Y (6) Huang H (7) Fu YX (8) Wang W
Author Info: (1) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijin
Author Info: (1) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. (2) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. (3) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. (4) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. (5) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. (6) School of Basic Medical Sciences, Tsinghua University, Beijing, China. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. (7) School of Basic Medical Sciences, Tsinghua University, Beijing, China. yangxinfu@tsinghua.edu.cn. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. yangxinfu@tsinghua.edu.cn. Changping Laboratory, Changping District, Beijing, China. yangxinfu@tsinghua.edu.cn. (8) School of Basic Medical Sciences, Tsinghua University, Beijing, China. wywang2022@tsinghua.edu.cn. State Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, China. wywang2022@tsinghua.edu.cn.
Citation: Nat Commun 2025 Oct 10 16:9029 Epub10/10/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41073424
Tags:
IL-2/IL-15 signaling induces NK cell production of FLT3LG augmenting anti-PD-1 immunotherapy
(1) Avanessian SC (2) van den Bijgaart RJE (3) Chew NW (4) Supper VM (5) Tang TT (6) Zhang Y (7) Zhao YQ (8) Abe K (9) Gauthier J (10) Barry KC
(1) Avanessian SC (2) van den Bijgaart RJE (3) Chew NW (4) Supper VM (5) Tang TT (6) Zhang Y (7) Zhao YQ (8) Abe K (9) Gauthier J (10) Barry KC
Author Info: (1) Fred Hutchinson Cancer Center, United States. (2) Fred Hutchinson Cancer Center, United States. (3) Fred Hutchinson Cancer Center, Seattle, WA, United States. (4) Massachusetts
Author Info: (1) Fred Hutchinson Cancer Center, United States. (2) Fred Hutchinson Cancer Center, United States. (3) Fred Hutchinson Cancer Center, Seattle, WA, United States. (4) Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States. (5) Fred Hutchinson Cancer Center, Seattle, WA, United States. (6) Fred Hutchinson Cancer Center, Seattle, United States. (7) Fred Hutchinson Cancer Center, United States. (8) Fred Hutchinson Cancer Center, Seattle, WA, United States. (9) Fred Hutchinson Cancer Center, Seattle, France. (10) Fred Hutchinson Cancer Center, Seattle, WA, United States.
Citation: Cancer Immunol Res 2025 Oct 13 Epub10/13/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41081432
Tags:
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia
(1) Sandn C (2) Landberg N (3) Pea-Martnez P (4) Thorsson H (5) Daga S (6) Puente-Moncada N (7) Rodriguez-Zabala M (8) von Palffy S (9) Rissler M (10) Lazarevic V (11) Juliusson G (12) Ohlin M (13) Hyrenius-Wittsten A (14) Orsmark-Pietras C (15) Lilljebjrn H (16) gerstam H (17) Fioretos T
(1) Sandn C (2) Landberg N (3) Pea-Martnez P (4) Thorsson H (5) Daga S (6) Puente-Moncada N (7) Rodriguez-Zabala M (8) von Palffy S (9) Rissler M (10) Lazarevic V (11) Juliusson G (12) Ohlin M (13) Hyrenius-Wittsten A (14) Orsmark-Pietras C (15) Lilljebjrn H (16) gerstam H (17) Fioretos T
Author Info: (1) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. carl.sanden@med.lu.se. (2) Division of Clinical Genetics, Department of Laborat
Author Info: (1) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. carl.sanden@med.lu.se. (2) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. Department of Hematology, Oncology and Radiation Physics, Skne University Hospital, Lund, Sweden. (3) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (4) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (5) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (6) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (7) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (8) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (9) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (10) Department of Hematology, Oncology and Radiation Physics, Skne University Hospital, Lund, Sweden. (11) Department of Hematology, Oncology and Radiation Physics, Skne University Hospital, Lund, Sweden. (12) Department of Immunotechnology, Lund University, Lund, Sweden. SciLifeLab Drug Discovery and Development Platform, Lund University, Lund, Sweden. (13) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (14) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Skne University Hospital, Region Skne, Lund, Sweden. (15) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. (16) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Skne University Hospital, Region Skne, Lund, Sweden. (17) Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. thoas.fioretos@med.lu.se. Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Skne University Hospital, Region Skne, Lund, Sweden. thoas.fioretos@med.lu.se.
Citation: Nat Cancer 2025 Oct 3 Epub10/03/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41044242
Tags:
Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors
(1) Niu D (2) Ma X (3) Zhu J (4) Sun L (5) Zhang S (6) Wu Y (7) Shan M (8) Dai X (9) Liao Y (10) Liu D (11) Lu L (12) Yang M (13) Zou Q (14) Lian J
(1) Niu D (2) Ma X (3) Zhu J (4) Sun L (5) Zhang S (6) Wu Y (7) Shan M (8) Dai X (9) Liao Y (10) Liu D (11) Lu L (12) Yang M (13) Zou Q (14) Lian J
Author Info: (1) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (2) Department of Clinical Biochemistry, Fac
Author Info: (1) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (2) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (3) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (4) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (5) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (6) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (7) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (8) College of Education and Science, Chongqing Normal University, Chongqing 400047, China. (9) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (10) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (11) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. (12) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. Electronic address: yangmingzhen0807@126.com. (13) National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. Electronic address: qmzou2007@163.com. (14) Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing 400038, China. Electronic address: lianjiqin@tmmu.edu.cn.
Citation: Cell Rep Med 2025 Oct 10 102413 Epub10/10/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41075789
Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer
(1) Gumpert N (2) Sagie S (3) Arnedo-Pac C (4) Babu T (5) Weller C (6) Gonzalez-Perez A (7) Wang Y (8) Michel Tod L (9) Levy R (10) Chen X (11) Greenberg P (12) Dayan-Rubinov M (13) Yakubovich E (14) Wasserman-Bartov T (15) Zerbib M (16) Gong J (17) Rebernick RJ (18) Oliveira Tercero A (19) Agundez Muriel L (20) Benedek G (21) Kedmi M (22) Oren R (23) Ben-Dor S (24) Levin Y (25) Troyanskaya OG (26) Munzur AD (27) Wyatt AW (28) Cieslik MP (29) Quigley DA (30) Van Allen EM (31) Anandasabapathy N (32) Mateo J (33) Yang X (34) Martnez-Jimnez F (35) Lopez-Bigas N (36) Samuels Y
To systematically identify recurrent clonal neoepitopes in treatment-resistant patients, Gumbert and Sagie et al. developed and applied the “Spot Neoantigens in Metastases” (SpotNeoMet) pipeline to metastatic cancer samples from the Hartwig Medical Foundation, using primary tumor samples from TCGA as control. Focusing on the common androgen receptor (AR) H875Y mutation in castration-resistant prostate cancer, they identified three neopeptides and validated their presentation and immunogenicity. Two cloned cognate TCRs were highly specific and led to killing of prostate cancer cells endogenously expressing AR H875Y in vitro and in vivo.
Contributed by Ute Burkhardt
(1) Gumpert N (2) Sagie S (3) Arnedo-Pac C (4) Babu T (5) Weller C (6) Gonzalez-Perez A (7) Wang Y (8) Michel Tod L (9) Levy R (10) Chen X (11) Greenberg P (12) Dayan-Rubinov M (13) Yakubovich E (14) Wasserman-Bartov T (15) Zerbib M (16) Gong J (17) Rebernick RJ (18) Oliveira Tercero A (19) Agundez Muriel L (20) Benedek G (21) Kedmi M (22) Oren R (23) Ben-Dor S (24) Levin Y (25) Troyanskaya OG (26) Munzur AD (27) Wyatt AW (28) Cieslik MP (29) Quigley DA (30) Van Allen EM (31) Anandasabapathy N (32) Mateo J (33) Yang X (34) Martnez-Jimnez F (35) Lopez-Bigas N (36) Samuels Y
To systematically identify recurrent clonal neoepitopes in treatment-resistant patients, Gumbert and Sagie et al. developed and applied the “Spot Neoantigens in Metastases” (SpotNeoMet) pipeline to metastatic cancer samples from the Hartwig Medical Foundation, using primary tumor samples from TCGA as control. Focusing on the common androgen receptor (AR) H875Y mutation in castration-resistant prostate cancer, they identified three neopeptides and validated their presentation and immunogenicity. Two cloned cognate TCRs were highly specific and led to killing of prostate cancer cells endogenously expressing AR H875Y in vitro and in vivo.
Contributed by Ute Burkhardt
ABSTRACT: New approaches that generate long-lasting therapeutic responses in therapy-resistant metastatic cancer patients are urgently needed. To address this challenge, we developed SpotNeoMet, a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neo-peptides presented by common HLAs. Using HLA-immunopeptidomics, we discovered three novel neopeptides derived from Androgen Receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCRs) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y specific TCRs are highly specific and kill prostate cancer cells presenting AR neo-peptides in vitro and in vivo. Our new pipeline identifies novel immunotherapy targets and potential treatment options for mCRPC patients. Moreover, SpotNeoMet offers a systematic route to identify 'HLA-peptide' pairs and their cognate TCRs across treatment-resistant cancers.
Author Info: (1) Weizmann Institute of Science, Rehovot, Israel. (2) Weizmann Institute of Science, Rehovot, Israel. (3) Institute for Research in Biomedicine, Barcelona, Spain. (4) Weizmann In
Author Info: (1) Weizmann Institute of Science, Rehovot, Israel. (2) Weizmann Institute of Science, Rehovot, Israel. (3) Institute for Research in Biomedicine, Barcelona, Spain. (4) Weizmann Institute of Science, Rehovot, Israel. (5) Weizmann Institute of Science, Rehovot, Israel. (6) Institute for Research in Biomedicine, Barcelona, Spain. (7) Princeton University, Princeton, NJ, United States. (8) Vall d'Hebron Institute of Oncology, Spain. (9) Weizmann Institute of Science, Rehovot, Israel. (10) Flatiron Institute, New York, NY, United States. (11) Weizmann Institute of Science, Rehovot, Israel. (12) Weizmann Institute of Science, Israel. (13) Weizmann Institute of Science, Rehovot, Israel. (14) Weizmann Institute of Science, Israel. (15) Weizmann Institute of Science, Rehovot, Israel, Israel. (16) University of Michigan-Ann Arbor, Ann Arbor, United States. (17) University of Michigan-Ann Arbor, Ann Arbor, United States. (18) Vall d'Hebron Institute of Oncology, Barcelona, Barcelona, Spain. (19) Vall d'Hebron Institute of Oncology, Spain. (20) Hadassah Medical Center, Jerusalem, Israel. (21) Weizmann Institute of Science, Israel. (22) Weizmann institute, Rehovot, Israel, Israel. (23) Weizmann Institute of Science, Rehovot, Israel, Israel. (24) Weizmann Institute of Science, Rehovot, Israel. (25) Princeton University, Princeton, NJ, United States. (26) University of British Columbia, Vancouver, British Columbia, Canada. (27) University of British Columbia, Vancouver, British Columbia, Canada. (28) University of Michigan-Ann Arbor, Ann Arbor, MI, United States. (29) University of California, San Francisco, San Francisco, CA, United States. (30) Dana-Farber Cancer Institute, Boston, MA, United States. (31) Weill Cornell Medicine, New York, NY, United States. (32) Vall d'Hebron Institute of Oncology, Barcelona, Spain. (33) Memorial Sloan Kettering Cancer Center, United States. (34) Vall d'Hebron Institute of Oncology, Spain. (35) Institute for Research in Biomedicine, Barcelona, Spain. (36) Weizmann Institute of Science, Rehovot, Israel.
Citation: Cancer Discov 2025 Oct 8 Epub10/08/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41056506
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases
(1) Keenan BP (2) Qiao G (3) Kunda N (4) Kone L (5) Guldberg SM (6) Todeschini L (7) Kumar P (8) Pollini T (9) Hernandez S (10) Qin J (11) Fong L (12) Spitzer MH (13) Prabhakar BS (14) Maker AV
Keenan and Qiao et al. showed in mouse models of colorectal liver metastases (CRLMs, which are CTLA-4high) that anti-CTLA-4 (but not anti-PD-1) treatment controlled LIGHT-overexpressing CRLMs by generating systemic and intratumoral immune activation. scRNAseq, CyTOF, and flow cytometry showed that the LIGHT/anti-CTLA-4 combination remodeled the TME; promoted TIL migration into metastases, TLS development, activation and effector functions of T cells and DC maturation; decreased T cell exhaustion; depleted suppressive myeloid cells; and reduced Treg functionality, with some corresponding data in human CRC.
Contributed by Paula Hochman
(1) Keenan BP (2) Qiao G (3) Kunda N (4) Kone L (5) Guldberg SM (6) Todeschini L (7) Kumar P (8) Pollini T (9) Hernandez S (10) Qin J (11) Fong L (12) Spitzer MH (13) Prabhakar BS (14) Maker AV
Keenan and Qiao et al. showed in mouse models of colorectal liver metastases (CRLMs, which are CTLA-4high) that anti-CTLA-4 (but not anti-PD-1) treatment controlled LIGHT-overexpressing CRLMs by generating systemic and intratumoral immune activation. scRNAseq, CyTOF, and flow cytometry showed that the LIGHT/anti-CTLA-4 combination remodeled the TME; promoted TIL migration into metastases, TLS development, activation and effector functions of T cells and DC maturation; decreased T cell exhaustion; depleted suppressive myeloid cells; and reduced Treg functionality, with some corresponding data in human CRC.
Contributed by Paula Hochman
ABSTRACT: Colorectal cancer and liver metastases are a leading cause of cancer-related mortality. Overexpression of the immunostimulatory cytokine TNFSF14/LIGHT associates with improved survival and correlates with increased tumor-infiltrating lymphocytes in patients and a clinically relevant model of colorectal liver metastases. We demonstrate that LIGHT monotherapy activates T cells, but also induces T cell exhaustion and the recruitment of immunosuppressive elements. As colorectal liver metastases exhibit high levels of CTLA-4 expression, we combined LIGHT overexpression with anti-CTLA-4, leading to complete tumor control. The combination functions by homing tumor-infiltrating lymphocytes, inducing tumor antigen-specific T cells, and reversing T cell exhaustion. Whereas both LIGHT overexpression and anti-CTLA-4 increase tumor-promoting macrophages, the combination eliminates this population. The ability of LIGHT overexpression combined with CTLA-4 inhibition to reverse T cell exhaustion and myeloid cell suppression is supported by analysis of complementary patient cohorts and has strong clinical relevance, especially given that liver metastases contribute to immunotherapy resistance across various cancer types.
Author Info: (1) Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. (2) Department of Surgery, Division of Surgical
Author Info: (1) Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. (2) Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. (3) Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA. (4) Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA. (5) Departments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA. (6) Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. (7) Department of Microbiology & Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA. (8) Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. (9) Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. (10) Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA. (11) Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA. (12) Departments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA. Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA. Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. (13) Department of Microbiology & Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA. (14) Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.
Citation: Sci Adv 2025 Oct 10 11:eadv9161 Epub10/08/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41061056
Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas
(1) Hu J (2) Singh H (3) Jin Y (4) Zhang W (5) Wang J (6) Xia X (7) Somaiah N (8) Gorlick R (9) Li S
Across clinical sarcomas, collagen expression increased with tumor stage and associated with reduced patient survival. To treat ECM-rich tumors, Hu and Singh et al. modified TILs to express a cell-surface vimentin (CSV, sarcoma antigen)-targeting peptide linked to IL-12 (attIL12-TILs). Compared to standard TILs, attIL12-TILs improved IFNγ production, reduced tumor collagen expression, and boosted infiltration and tumor control in mouse sarcoma models. Inhibiting signaling by either TCRs or CSV abrogated these effects. Mechanistically, attIL12-TILs reduced tumor cell collagen levels via IFNγ inhibition of TGFβ-SMAD3 and CCKAR-pAKT pathways.
Contributed by Alex Najibi
(1) Hu J (2) Singh H (3) Jin Y (4) Zhang W (5) Wang J (6) Xia X (7) Somaiah N (8) Gorlick R (9) Li S
Across clinical sarcomas, collagen expression increased with tumor stage and associated with reduced patient survival. To treat ECM-rich tumors, Hu and Singh et al. modified TILs to express a cell-surface vimentin (CSV, sarcoma antigen)-targeting peptide linked to IL-12 (attIL12-TILs). Compared to standard TILs, attIL12-TILs improved IFNγ production, reduced tumor collagen expression, and boosted infiltration and tumor control in mouse sarcoma models. Inhibiting signaling by either TCRs or CSV abrogated these effects. Mechanistically, attIL12-TILs reduced tumor cell collagen levels via IFNγ inhibition of TGFβ-SMAD3 and CCKAR-pAKT pathways.
Contributed by Alex Najibi
ABSTRACT: Tumor-targeted T cell therapies of various types have been booming, but T cell therapy is limited by its inability to penetrate the collagen barrier surrounding tumors. The destruction of tumor collagen is significant because collagen both suppresses T cells and contributes to the formation of the extracellular matrix. Our previously reported cell-surface vimentin (CSV)-targeted and membrane-anchored interleukin 12-armed (attIL12) T cells can reduce collagen production by killing cancer-associated fibroblasts, but fail to reduce collagen expression by tumor cells, resulting in resistance to attIL12-T cell treatment. In this study, we found that CCKAR directly boosts collagen production by tumor cells in vitro and in vivo. attIL12-modified tumor-infiltrating lymphocytes (TILs) disabled collagen production by CCKAR-high autologous tumor cells in vitro and sarcoma patient-derived xenografts (PDXs) in vivo. This disruption of collagen production by tumor cells by attIL12-TILs overcomes resistance to attIL12-T cell treatment and required a simultaneous interaction between the CSV on autologous tumor cells, which is targeted by attIL12, and human leukocyte antigen-T cell receptor on attIL12-TILs; When either interaction was abrogated, collagen production and CCKAR expression were not shut down. Mechanistically, the interaction between attIL12-TILs and autologous tumor cells induced interferon gamma production synergistically, which in combination with CCKAR downregulation reduced collagen expression through suppression of both transforminggrowth factor beta-stimulated SMAD activation and CCKAR-AKT signaling. Diminishing collagen expression from tumor cells significantly increased T cell infiltration and improved tumor growth inhibition in PDX sarcomas. Thus, this attIL12-TIL therapy holds great clinical potential for boosting T cell infiltration in high-grade, collagen-rich tumors.
Author Info: (1) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (2) Division of Pediatrics, Department of Pedia
Author Info: (1) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (2) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (3) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (4) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (5) Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (6) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (7) Division of Cancer Medicine, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (8) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. (9) Division of Pediatrics, Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Citation: Proc Natl Acad Sci U S A 2025 Oct 14 122:e2507542122 Epub10/06/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41052334
CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success
(1) Ludin A (2) Stirtz GL (3) Tal A (4) Nirmal AJ (5) Pfaff KL (6) Manos M (7) Besson N (8) Eskndir N (9) Porter B (10) Jones SM (11) Faulkner HM (12) Gong Q (13) Liu S (14) Barrera I (15) Wu L (16) Pessoa Rodrigues C (17) Sahu A (18) Jerison E (19) Alessi JV (20) Ricciuti B (21) Richardson DS (22) Weiss JD (23) Moreau HM (24) Stanhope ME (25) Afeyan AB (26) Sefton J (27) McCall WD (28) Formato E (29) Yang S (30) Zhou Y (31) Hoytema van Konijnenburg DP (32) Cole HL (33) Cordova M (34) Deng L (35) Rajadhyaksha M (36) Quake SR (37) Awad MM (38) Chen F (39) Wucherpfennig KW (40) Sorger PK (41) Hodi FS (42) Rodig SJ (43) Murphy GF (44) Zon LI
(1) Ludin A (2) Stirtz GL (3) Tal A (4) Nirmal AJ (5) Pfaff KL (6) Manos M (7) Besson N (8) Eskndir N (9) Porter B (10) Jones SM (11) Faulkner HM (12) Gong Q (13) Liu S (14) Barrera I (15) Wu L (16) Pessoa Rodrigues C (17) Sahu A (18) Jerison E (19) Alessi JV (20) Ricciuti B (21) Richardson DS (22) Weiss JD (23) Moreau HM (24) Stanhope ME (25) Afeyan AB (26) Sefton J (27) McCall WD (28) Formato E (29) Yang S (30) Zhou Y (31) Hoytema van Konijnenburg DP (32) Cole HL (33) Cordova M (34) Deng L (35) Rajadhyaksha M (36) Quake SR (37) Awad MM (38) Chen F (39) Wucherpfennig KW (40) Sorger PK (41) Hodi FS (42) Rodig SJ (43) Murphy GF (44) Zon LI
ABSTRACT: T cell-mediated tumor killing underlies immunotherapy success. Here, we used long-term in vivo imaging and high-resolution spatial transcriptomics of zebrafish endogenous melanoma, as well as multiplex imaging of human melanoma, to identify domains facilitating the immune response during immunotherapy. We identified cancer regions of antigen presentation and T cell engagement and retention (CRATERs) as pockets at the stroma-melanocyte boundaries of zebrafish and human melanoma. CRATERs are rich in antigen-recognition molecules, harboring the highest density of CD8(+) T cells in tumors. In zebrafish, CD8(+) T cells formed prolonged interactions with melanoma cells within CRATERs, characteristic of antigen recognition. Following immunostimulatory treatment, CRATERs expanded, becoming the major sites of activated CD8(+) T cell accumulation and tumor killing. In humans, elevation in CRATER density in biopsies following immune checkpoint blockade (ICB) therapy correlated with a clinical response to therapy. CRATERs are structures that show active tumor killing and may be useful as a diagnostic indicator for immunotherapy success.
Author Info: (1) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Ho
Author Info: (1) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. (2) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (3) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (4) Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. (5) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (6) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (7) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (8) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (9) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (10) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (11) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (12) Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA. (13) Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. (14) Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA. (15) Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (16) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. (17) Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. (18) Department of Physics, University of Chicago, Chicago, IL 60637, USA. (19) Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (20) Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (21) Harvard Center for Biological Imaging, Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA. (22) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (23) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (24) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (25) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (26) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (27) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (28) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. (29) Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. (30) Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. (31) Division of Immunology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. (32) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA. (33) Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. (34) Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. (35) Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. (36) Department of Bioengineering and Applied Sciences, Stanford University, Stanford, CA 94305, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. (37) Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (38) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA. (39) Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. (40) Ludwig Center at Harvard, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. (41) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Parker Institute for Cancer Immunotherapy, Boston, MA, USA. (42) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. (43) Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. (44) Harvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: leonard.zon@enders.tch.harvard.edu.
Citation: Cell 2025 Oct 17 Epub10/17/2025
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/41109214